Clinical trial NCT02731690: A Study to Evaluate the Safety of Aceneuramic Acid Extended Release (Ace-ER; UX001) Tablets in Glucosamine (UDP-N-acetyl)-2-Epimerase (GNE) Myopathy (GNEM) (Also Known as Hereditary Inclusion Body Myopathy [HIBM]) Patients With Severe Ambulatory Impairment
Official title: A Phase 2 Open-label Study to Evaluate the Safety of Aceneuramic Acid Extended Release (Ace-ER) Tablets in GNE Myopathy (GNEM) (Also Known as Hereditary Inclusion Body Myopathy (HIBM)) Patients With Severe Ambulatory Impairment
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Hereditary Inclusion Body Myopathy
Distal Myopathy With Rimmed Vacuoles
Distal Myopathy, Nonaka Type
GNE Myopathy
Quadriceps Sparing Myopathy
Inclusion Body Myopathy 2
Keywords: GNE Myopathy
Nonaka
GNEM
Hereditary Inclusion Body Myopathy
HIBM
DMRV
QSM
Lead sponsor: Ultragenyx Pharmaceutical Inc
Sponsor class: INDUSTRY
First posted: 2016-04-07
Enrollment: 42
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The primary objective of this Phase 2 study is to evaluate the safety of open-label 6 g/day Ace-ER in GNEM participants with severe ambulatory impairment.


Eligibility criteria: Inclusion Criteria:

* Male or female, aged ≥ 18 years old
* Willing and able to provide written, signed informed consent after the nature of the study has been explained, and before any research-related procedures are conducted
* Have a documented diagnosis of GNEM, HIBM, distal myopathy with rimmed vacuoles (DMRV), or Nonaka disease due to previously demonstrated mutations in the gene encoding the GNE/N-acetylmannosamine kinase (MNK) enzyme (genotyping will not be conducted in this study).
* Should meet the criteria for severe ambulatory impairment defined below:

  * Unable to rise from a seated position to standing without help from another person, assistive device(s), stationary object, or other support AND
  * Unable to walk without the assistance of another person OR if able to walk (use of assistive device(s) permitted), requires at least 2 minutes to walk 40 meters (one full lap of the 6-minute walk test \[6MWT\] course) AND
  * Use of wheelchair or scooter for activities outside of the home or unable to leave the home independently
* Willing and able to comply with all study procedures
* Participants of child-bearing potential or with partners of child-bearing potential who have not undergone a bilateral salpingo-oophorectomy and are sexually active must consent to use highly effective method of contraception as determined by the site investigator (i.e. oral hormonal contraceptives, patch hormonal contraceptives, vaginal ring, intrauterine device, physical double-barrier methods, surgical hysterectomy, vasectomy, tubal ligation or true abstinence (when this is in line with the preferred and usual lifestyle of the subject) which means not having sex because the subject chooses not to), from the period following the signing of the informed consent through 30 days after last dose of study drug
* Females of childbearing potential must have a negative pregnancy test at Screening and be willing to have additional pregnancy tests during the study. Females considered not of childbearing potential include those who have been in menopause for at least two years, have had tubal ligation at least one year prior to Screening, or who have had a total hysterectomy or bilateral salpingo-oophorectomy

Exclusion Criteria:

* Ingestion of N-acetyl-D-mannosamine (ManNAc), SA, or related metabolites; intravenous immunoglobulin (IVIG); or anything that can be metabolized to produce SA in the body within 60 days prior to the Screening Visit
* Prior participation in a clinical trial involving treatment with Ace-ER/placebo and/or Sialic Acid immediate release (SA-IR) in the past year
* Has had any hypersensitivity to aceneuramic acid or its excipients that, in the judgment of the investigator, places the subject at increased risk for adverse effects
* Has serum transaminase (i.e. aspartate aminotransferase \[AST\] or gamma-glutamyl transpeptidase \[GGT\]) levels greater than 3X the upper limit of normal (ULN) for age/gender, or serum creatinine of greater than 2X ULN at Screening
* Pregnant or breastfeeding at Screening or planning to become pregnant (self or partner) at any time during the study
* Use of any investigational product or investigational medical device within 30 days prior to Screening, or anticipated requirement for any investigational agent prior to completion of all scheduled study assessments
* Has a condition of such severity and acuity, in the opinion of the investigator, that it warrants immediate surgical intervention or other treatment or may not allow safe participation in the study
* Has a concurrent disease, active suicidal ideation, or other condition that, in the view of the investigator, places the subject at high risk of poor treatment compliance or of not completing the study, or would interfere with study participation or would affect safety

Primary outcomes:
measure: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Discontinuation
timeFrame: 48 Weeks (plus 30 [+5] days for participants not enrolling in extension study)
Secondary outcomes:
measure: Number of Participants Taking Prior and Concomitant Medications
timeFrame: 48 weeks
measure: Number of Participants With Clinically Significant Changes From Baseline In Physical Examinations
timeFrame: 48 weeks
measure: Number of Participants With Clinically Significant Changes From Baseline In Vital Signs
timeFrame: 48 weeks
measure: Number of Participants With Clinically Significant Changes From Baseline In Clinical Laboratory Results
timeFrame: 48 weeks
measure: Number of Participants With Overall Suicidal Behaviors and/or Ideation at Baseline and Post-Baseline
timeFrame: 48 weeks
measure: Change From Baseline in GNEM-FAS Expanded Version Mobility Domain Subscale Scores Over Time
timeFrame: Baseline, Weeks 12, 24, 36, and 48
measure: Change From Baseline in GNEM-FAS Expanded Version Upper Extremity Domain Subscale Scores Over Time
timeFrame: Baseline, Weeks 12, 24, 36, and 48
measure: Change From Baseline in GNEM-FAS Expanded Version Self-Care Domain Subscale Scores Over Time
timeFrame: Baseline, Weeks 12, 24, 36, and 48
measure: Change From Baseline in GNEM-FAS Expanded Version Total Scores Over Time
timeFrame: Baseline, Weeks 12, 24, 36, and 48
measure: Change From Baseline in HHD Raw Strength (Grip) Over Time
timeFrame: Baseline, Weeks 12, 24, 36, and 48
measure: Change From Baseline in HHD Raw Strength (Shoulder Abductors) Over Time
timeFrame: Baseline, Weeks 12, 24, 36, and 48
measure: Change From Baseline in HHD Raw Strength (Wrist Extensors) Over Time
timeFrame: Baseline, Weeks 12, 24, 36, and 48
measure: Change From Baseline in HHD Muscle Strength in Knee Extensors Over Time
timeFrame: Baseline, Weeks 12, 24, 36, and 48
measure: Change From Baseline in HHD Raw Strength (Key Pinch) Over Time
timeFrame: Baseline, Weeks 12, 24, 36, and 48
Other outcomes:
Locations:
city: Orange
country: United States
facility: University of California, Irvine
state: California
city: Saint Louis
country: United States
facility: Washington University, St. Louis
state: Missouri
city: New York
country: United States
facility: NYU Langone Medical Center
state: New York
city: Sofia
country: Bulgaria
facility: University Alexandrovska, Bulgaria
city: Hamilton
country: Canada
facility: McMaster University
state: Ontario
Study officials:
affiliation: Ultragenyx Pharmaceutical Inc
name: Medical Director
role: STUDY_DIRECTOR
References: